J&J’s Cordis obtains CE Mark for Renlane renal denervation device

25 February 2014 (Last Updated February 25th, 2014 01:00)

Johnson & Johnson subsidiary Cordis has obtained the European CE Mark for its Renlane renal denervation system designed for the treatment of adult patients (>18 years) with drug-resistant hypertension to denervate the renal arteries to reduce blood pressure.

cordis

Johnson & Johnson subsidiary Cordis has obtained the European CE Mark for its Renlane renal denervation system designed for the treatment of adult patients (>18 years) with drug-resistant hypertension to denervate the renal arteries to reduce blood pressure.

The Renlane renal denervation catheter features five irrigated electrodes located at the tip of the ablation catheter and is used in conjunction with the Renlane Multi-Channel RF generator for energy delivery.

The Renlane system includes a helical shaped, irrigated, multi-electrode ablation catheter with a multi-channel radiofrequency ablation system.

The minimally invasive procedure involves applying radiofrequency ablation through a catheter to the renal arteries that supply the kidneys with blood, hopefully causing the kidneys to produce less of the hormones that cause chronic high blood pressure.

Dr Hannes Reuter at the University of Cologne Hospital in Germany, has made the first successful European use of the Renlane renal denervation system, using it to treat patients with high blood pressure who had proved resistant to traditional drug therapies.

All procedures were performed successfully and patients were discharged after one day.

University of Cologne, Germany, Dr Reuter said the novel technological design of the Renlane renal denervation catheter with its configuration of five electrodes and irrigated technology, allows for shorter procedure duration, sparing of contrasting dye and likely more protection of the endothelium.

"The design of the catheter makes handling the device very easy."

"The design of the catheter makes handling the device very easy," Dr Reuter said.

According to World Health Organization estimates, approximately one billion people worldwide live with hypertension or high blood pressure and is the cause of one in every eight deaths, making hypertension the third leading cause of death worldwide.

It is estimated that between 15% and 30% of treated hypertensive patients are resistant to traditional drug therapy, defined as failure to respond to three or more drugs.

The International Society of Hypertension estimates the annual cost of healthcare expenditure directly related to elevated blood pressure to be almost $500bn.

Cordis worldwide president Celine Martin said: "We are pleased to make our RENLANE Renal Denervation System available to European clinicians in need of solutions for patients who do not respond to traditional drug therapy.

"And we are looking forward to gaining more experience with this therapy and making it available to more patients in need of treatment around the world."


Image: Cordis corporate headquarters, New Jersey, US. Photo: courtesy of Cordisemea.